Ultragenyx Pharmaceutical Inc. (RARE) stock
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Earnings
Ultragenyx Pharmaceutical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Ultragenyx Pharmaceutical's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 11, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026after the close | $173.00M | +8.1% | -$1.16 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | $214.00M | +28.9% | -$0.90 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $136.00M | -2.2% | -$1.84 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 12, 2026after the close | $207.00M | +25.5% | -$1.29 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | $160.00M | +15.1% | -$1.81 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $166.00M | +12.9% | -$1.17 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $139.00M | +27.5% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 13, 2025after the close | $165.00M | +29.9% | -$1.39 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024after the close | $139.00M | +41.7% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | $147.00M | +35.7% | -$1.52 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024after the close | $109.00M | +8.5% | -$2.03 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024after the close | $127.00M | +22.9% | -$1.52 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $98.10M | +8.2% | -$2.23 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $108.30M | +21.3% | -$2.25 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $100.50M | +25.8% | -$2.33 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 16, 2023after the close | $103.30M | +23.9% | -$2.16 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022after the close | $90.70M | +11.2% | -$3.50 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 28, 2022after the close | $89.30M | – | -$2.26 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $79.90M | – | -$2.19 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 10, 2022after the close | $83.40M | – | -$1.79 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021after the close | $81.60M | – | -$1.08 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 2, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Jan 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 27, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Ultragenyx Pharmaceutical's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Dojolvi revenue | FY2026 | $100.00M – $110.00M | $100.00M – $110.00M | Lowered | Nov 3, 2026 |
| Dojolvi revenue | FY2026 | $100.00M – $110.00M | $100.00M – $110.00M | Lowered | Aug 4, 2026 |
Guidance vs results
The last range Ultragenyx Pharmaceutical gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $640.00M – $670.00M | $672.00MΣ4Q | Above range |
Guidance history
Every forecast Ultragenyx Pharmaceutical put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 3, 2026 | Dojolvi revenue | FY2026 | $100.00M – $110.00M | Lowered |
| Nov 3, 2026 | Crysvita revenue | FY2026 | $500.00M – $520.00M | Lowered |
| Nov 3, 2026 | total revenue | FY2026 | $730.00M – $760.00M | Raised |
| Aug 4, 2026 | Dojolvi revenue | FY2026 | $100.00M – $110.00M | Lowered |
| Aug 4, 2026 | Crysvita revenue | FY2026 | $500.00M – $520.00M | Lowered |
| Aug 4, 2026 | total revenue | FY2026 | $730.00M – $760.00M | Raised |
| May 5, 2026 | Dojolvi revenue | FY2026 | $100.00M – $110.00M | Lowered |
| May 5, 2026 | Crysvita revenue | FY2026 | $500.00M – $520.00M | Lowered |
| May 5, 2026 | total revenue | FY2026 | $730.00M – $760.00M | New |
| Feb 12, 2026 | Dojolvi revenue | FY2026 | $100.00M – $110.00M | Lowered |
| Feb 12, 2026 | Crysvita revenue | FY2026 | $500.00M – $520.00M | Lowered |
| Feb 12, 2026 | Total revenues, excluding potential revenue from new product launches | FY2026 | $730.00M – $760.00M | New |
| Nov 4, 2025 | Crysvita revenue | FY2025 | $460.00M – $480.00M | New |
| Nov 4, 2025 | Dojolvi revenue | FY2025 | $90.00M – $100.00M | Lowered |
| Nov 4, 2025 | Total revenue | FY2025 | $640.00M – $670.00M | New |
| Aug 5, 2025 | Total revenues | FY2025 | +14% – +20% | Reaffirmed |
| Aug 5, 2025 | Total revenue | FY2025 | $640.00M – $670.00M | Raised |
| Aug 5, 2025 | Crysvita revenue | FY2025 | $460.00M – $480.00M | Lowered |
| Aug 5, 2025 | Dojolvi revenue | FY2025 | $90.00M – $100.00M | Lowered |
| May 6, 2025 | Revenues | FY2025 | +14% – +20% | Reaffirmed |
| May 6, 2025 | Total revenue | FY2025 | $640.00M – $670.00M | Raised |
| May 6, 2025 | Crysvita revenue | FY2025 | $460.00M – $480.00M | Lowered |
| May 6, 2025 | Dojolvi revenue | FY2025 | $90.00M – $100.00M | Lowered |
| Feb 13, 2025 | Total revenue | FY2025 | $640.00M – $670.00M | Reaffirmed |
| Feb 13, 2025 | Crysvita revenue | FY2025 | $460.00M – $480.00M | Lowered |
| Feb 13, 2025 | Dojolvi revenue | FY2025 | $90.00M – $100.00M | Lowered |
| Jan 13, 2025 | revenues | FY2025 | +14% – +20% | New |
| Jan 13, 2025 | total revenue | FY2025 | $640.00M – $670.00M | New |
| Nov 5, 2024 | Net Cash Used in Operations | FY2024 | $400.00M | New |
| Nov 5, 2024 | Total revenue | FY2024 | $530.00M – $550.00M | Reaffirmed |
| Nov 5, 2024 | Crysvita revenue | FY2024 | $375.00M – $400.00M | Lowered |
| Nov 5, 2024 | Dojolvi revenue | FY2024 | $75.00M – $80.00M | Lowered |
| Aug 1, 2024 | Total revenue | FY2024 | $530.00M – $550.00M | Raised |
| May 2, 2024 | Total revenue | FY2024 | $500.00M – $530.00M | Raised |
| Feb 15, 2024 | Total revenue | FY2024 | $500.00M – $530.00M | New |
| Feb 15, 2024 | Crysvita revenue | FY2024 | $375.00M – $400.00M | Lowered |
| Feb 15, 2024 | Dojolvi revenue | FY2024 | $75.00M – $80.00M | Lowered |
| Nov 2, 2023 | Net Cash Used in Operations | FY2023 | $425.00M | Raised |
| Nov 2, 2023 | Total revenue | FY2023 | $425.00M – $450.00M | Raised |
| Nov 2, 2023 | Crysvita revenue | FY2023 | $325.00M – $340.00M | Lowered |
| Nov 2, 2023 | Dojolvi revenue | FY2023 | $65.00M – $75.00M | Lowered |
| Aug 3, 2023 | Net Cash Used in Operations | FY2023 | $400.00M | New |
| Aug 3, 2023 | Total revenue | FY2023 | $425.00M – $450.00M | Raised |
| Aug 3, 2023 | Crysvita revenue | FY2023 | $325.00M – $340.00M | Lowered |
| Aug 3, 2023 | Dojolvi revenue | FY2023 | $65.00M – $75.00M | Lowered |
| May 4, 2023 | Total revenue | FY2023 | $425.00M – $450.00M | Reaffirmed |
| May 4, 2023 | Crysvita revenue | FY2023 | $325.00M – $340.00M | Lowered |
| May 4, 2023 | Dojolvi revenue | FY2023 | $65.00M – $75.00M | Lowered |
| Feb 16, 2023 | Total revenue | FY2023 | $425.00M – $450.00M | New |
| Nov 2, 2022 | revenue for Crysvita in Ultragenyx territories | FY2022 | $250.00M – $260.00M | Raised |
| Nov 2, 2022 | Dojolvi revenue | FY2022 | $55.00M – $65.00M | Lowered |
| Jul 28, 2022 | revenue for Crysvita in Ultragenyx territories | FY2022 | $250.00M – $260.00M | Raised |
| Jul 28, 2022 | Dojolvi revenue | FY2022 | $55.00M – $65.00M | Lowered |
| May 5, 2022 | revenue for Crysvita in Ultragenyx territories | FY2022 | $250.00M – $260.00M | Raised |
| May 5, 2022 | Dojolvi revenue | FY2022 | $55.00M – $65.00M | Lowered |
| Feb 10, 2022 | revenue for Crysvita in Ultragenyx territories | FY2022 | $250.00M – $260.00M | New |
| Feb 10, 2022 | Dojolvi revenue | FY2022 | $55.00M – $65.00M | Lowered |
| Nov 2, 2021 | Crysvita revenue | FY2021 | $180.00M – $190.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Ultragenyx Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?